Literature DB >> 2148808

Molecular definition of interaction sites on human IgG for Fc receptors (huFc gamma R).

R Jefferis1, J Lund, J Pound.   

Abstract

Evidence from several experimental approaches allows us to conclude that the primary amino acid sequence of the lower hinge region (residues 234-237) of human IgG molecules determines recognition by human Fc gamma RI, Fc gamma RII and Fc gamma RIII. Glycosylation of the CH2 domain is also essential, although the carbohydrate is not accessible for direct interaction with ligands. The role of the carbohydrate moiety may be to maintain a protein conformation that allows accessibility to amino acid side chains essential for ligand recognition and binding. It appears logical that the evolutionarily-related Fc gamma R molecules should interact with overlapping non-identical sites on the IgG molecule.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2148808     DOI: 10.1016/0161-5890(90)90027-w

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  18 in total

1.  Second Jenner international glycoimmunology meeting.

Authors: 
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

2.  Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies.

Authors:  M S Chappel; D E Isenman; M Everett; Y Y Xu; K J Dorrington; M H Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

3.  Immunoglobulin subclass determines ability of immunoglobulin (Ig)G to capture and activate neutrophils presented as normal human IgG or disease-associated anti-neutrophil cytoplasm antibody (ANCA)-IgG.

Authors:  T Pankhurst; G Nash; J Williams; R Colman; A Hussain; C Savage
Journal:  Clin Exp Immunol       Date:  2011-03-10       Impact factor: 4.330

4.  Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Authors:  M Hezareh; A J Hessell; R C Jensen; J G van de Winkel; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

Authors:  M G Wing; T Moreau; J Greenwood; R M Smith; G Hale; J Isaacs; H Waldmann; P J Lachmann; A Compston
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

Review 6.  Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?

Authors:  Randall J Brezski; Robert E Jordan
Journal:  MAbs       Date:  2010-05-23       Impact factor: 5.857

7.  Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors.

Authors:  Nikki Cheng; Dana Brantley; Wei Bin Fang; Hua Liu; William Fanslow; Douglas Pat Cerretti; Katrin N Bussell; Alastair Reith; Dowdy Jackson; Jin Chen
Journal:  Neoplasia       Date:  2003 Sep-Oct       Impact factor: 5.715

8.  Glycosylation and functional activity of anti-D secreted by two human lymphoblastoid cell lines.

Authors:  D Cant; J Barford; C Harbour; A Fletcher; N Packer; A Gooley
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

9.  Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge.

Authors:  Randall J Brezski; Omid Vafa; Diane Petrone; Susan H Tam; Gordon Powers; Mary H Ryan; Jennifer L Luongo; Allison Oberholtzer; David M Knight; Robert E Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-07       Impact factor: 11.205

10.  Engineered protease-resistant antibodies with selectable cell-killing functions.

Authors:  Michelle Kinder; Allison R Greenplate; Katharine D Grugan; Keri L Soring; Katharine A Heeringa; Stephen G McCarthy; Gregory Bannish; Meredith Perpetua; Frank Lynch; Robert E Jordan; William R Strohl; Randall J Brezski
Journal:  J Biol Chem       Date:  2013-08-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.